Identifying and Targeting New Actionable Drivers in NSCLC

Identifying and Targeting New Actionable Drivers in NSCLC

Emerging Strategies and Clinical Implications

Not a member of My prIME? Join now for instant access.

Meeting Overview

This interactive live symposium will focus on emerging therapeutic options targeting new actionable drivers in non-small cell cancer (NSCLC). Expert faculty will present updates on advances in molecular testing, such as next-generation sequencing and liquid biopsy, new data on emerging agents, and how these new data should be applied in clinical practice.

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Date and Location

Sunday, June 2, 2019
6:00 PM – 8:30 PM

Salon A 1&2, LL
The Hilton Chicago
720 S Michigan Ave
Chicago, Illinois 60605



6:00 PM – 8:30 PM
Sunday, June 2, 2019



Chicago, Illinois, United States



2.0 AMA PRA Category 1 Credits™

6:00 PM Registration and dinner
6:30 PM Welcome and introduction
Ross Camidge, MD, PhD
6:35 PM Warm-up quiz
Ross Camidge, MD, PhD
6:40 PM Setting the stage: How precision medicine transformed the treatment algorithm of advanced NSCLC thus far
Ross Camidge, MD, PhD
6:50 PM Identifying new actionable targets: Use of broad molecular profiling in daily practice
Keith Kerr, MBChB, FRCPath
7:11 PM MET-altered NSCLC: Current and emerging treatment strategies
Paul Paik, MD
7:32 PM Updates on targeting HER2, RET, and NTRK in advanced NSCLC
Frank Griesinger, MD, PhD
7:57 PM Managing acquired resistance to EGFR-TKI: Focus on targeting bypass resistance mechanisms
James C-H Yang, MD, PhD
8:18 PM Quiz questions revisited and faculty commentary
Ross Camidge, MD, PhD
8:25 PM prIME Points™
Ross Camidge, MD, PhD
8:30 PM Adjourn



  • Ross Camidge, MD, PhDUniversity of Colorado Cancer Center
    Aurora, Colorado, United States
  • Faculty

  • Frank Griesinger, MD, PhDPius-Hospital Oldenburg
    Oldenburg, Germany
  • Keith Kerr, MBChB, FRCPathAberdeen University Medical School
    Aberdeen Royal Infirmary
    Aberdeen, Scotland
  • Paul K. Paik, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • James C-H Yang, MD, PhDNational Taiwan University Hospital
    National Taiwan University Cancer Center
    Taipei, Taiwan

This educational activity is designed for oncologists (community and academic), pulmonologists, pathologists, oncology fellows, and other healthcare professionals involved in the management of patients with lung cancer.

After successful completion of this educational activity, participants should be able to:

  • Assess the role of broad molecular profiling and the use of liquid biopsy in advanced NSCLC
  • Select and evaluate treatment options for patients identified with oncogene drivers such as MET exon 14–skipping mutations or MET amplification, RET, HER2, and NTRK
  • Analyze efficacy and safety data of emerging agents in patients harboring new driver mutations, and discuss clinical applications of new data
  • Explain strategies to overcome acquired resistance to targeted therapy such as EGFR-TKI, including emerging combination targeted-treatment approaches

This educational activity is supported by a grant from EMD Serono, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Americans With Disabilities Act/Accessibility

Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact us prior to the live event using the contact form.


Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.